Last reviewed · How we verify
Placebo for Ipatasertib
Placebo for Ipatasertib is a Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 3 development for Control arm in ipatasertib clinical trials (specific indication depends on the trial protocol).
This is a placebo control and has no active pharmacological mechanism.
This is a placebo control and has no active pharmacological mechanism. Used for Control arm in ipatasertib clinical trials (specific indication depends on the trial protocol).
At a glance
| Generic name | Placebo for Ipatasertib |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (ipatasertib, an AKT inhibitor) through comparison. It allows researchers to distinguish true drug effects from natural disease progression and psychological effects.
Approved indications
- Control arm in ipatasertib clinical trials (specific indication depends on the trial protocol)
Common side effects
Key clinical trials
- Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (PHASE3)
- A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer (PHASE3)
- A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (PHASE3)
- Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy (PHASE1, PHASE2)
- A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (PHASE2)
- A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors (PHASE2)
- A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Ipatasertib CI brief — competitive landscape report
- Placebo for Ipatasertib updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about Placebo for Ipatasertib
What is Placebo for Ipatasertib?
How does Placebo for Ipatasertib work?
What is Placebo for Ipatasertib used for?
Who makes Placebo for Ipatasertib?
What development phase is Placebo for Ipatasertib in?
Related
- Manufacturer: Hoffmann-La Roche — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Control arm in ipatasertib clinical trials (specific indication depends on the trial protocol)
- Compare: Placebo for Ipatasertib vs similar drugs
- Pricing: Placebo for Ipatasertib cost, discount & access